RYTARY
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RYTARY (RYTARY).
Levodopa is a dopamine precursor that crosses the blood-brain barrier and is converted to dopamine in the brain, thereby increasing dopamine levels in the substantia nigra and striatum. Carbidopa inhibits peripheral decarboxylation of levodopa, reducing peripheral side effects and increasing levodopa availability to the brain.
| Metabolism | Levodopa is extensively metabolized by aromatic L-amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) in the periphery and brain. Carbidopa inhibits peripheral AAAD. Major metabolic pathways include decarboxylation and O-methylation. |
| Excretion | Renal (approximately 80% as metabolites, including 3-O-methyldopa and other conjugates; <1% unchanged); biliary/fecal (approximately 10-15%) |
| Half-life | Carbidopa: 2-3 hours; Levodopa: 1-2 hours (immediate-release component), levodopa elimination half-life extended to approximately 5-6 hours for the extended-release component; clinical context: allows once-daily dosing despite short half-life of IR component due to ER formulation |
| Protein binding | Levodopa: approximately 10-30% (albumin); Carbidopa: approximately 36% (albumin) |
| Volume of Distribution | Levodopa: 0.66-1.4 L/kg (carbidopa: not well-characterized); Vd indicates extensive tissue distribution, particularly to muscle and brain |
| Bioavailability | Levodopa: Approximately 70-80% (from immediate-release component with carbidopa); overall absorption from RYTARY's extended-release formulation is about 80% relative to the same total dose of immediate-release carbidopa/levodopa |
| Onset of Action | Oral: Initial effect may be seen within 30 minutes to 2 hours for immediate-release component; peak plasma concentrations for total levodopa occur at approximately 3-5 hours for the extended-release component |
| Duration of Action | Oral: Approximately 24 hours with once-daily dosing due to extended-release formulation; clinical note: some patients may experience wearing-off requiring dose adjustments or additional IR therapy |
Initial: 23.75 mg/95 mg orally three times daily for 3 days, then increase to 36.25 mg/145 mg three times daily. Titrate based on response and tolerability. Maximum dose: 97.5 mg/390 mg three times daily.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | No dose adjustment for mild to moderate renal impairment. Severe renal impairment (eGFR <30 mL/min/1.73 m²): not recommended due to potential accumulation of carbidopa and levodopa. |
| Liver impairment | Child-Pugh A: no adjustment. Child-Pugh B: use with caution, consider reducing dose by 50%. Child-Pugh C: not recommended. |
| Pediatric use | Safety and efficacy not established in pediatric patients (age <18 years). |
| Geriatric use | Initiate at low end of dosing range; monitor for hallucinations, dizziness, and hypotension. Dose titration should be gradual due to increased sensitivity to levodopa and risk of adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RYTARY (RYTARY).
| Breastfeeding | Levodopa is excreted into human milk. M/P ratio not established. Potential for adverse effects in nursing infant (dystonia, growth impairment). Caution advised; avoid breastfeeding due to risk of dopamine receptor stimulation in infant. |
| Teratogenic Risk | Pregnancy Category C. First trimester: Limited human data; animal studies show fetal developmental toxicity including malformations. Second/third trimester: Risk of adverse maternal effects (e.g., dyskinesias) and potential fetal effects due to levodopa crossing placenta. Use only if benefit outweighs risk. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Concurrent use with non-selective MAO inhibitors (e.g., phenelzine, tranylcypromine) - must discontinue at least 2 weeks prior to starting RYTARY","Known hypersensitivity to carbidopa, levodopa, or any component of the formulation","Narrow-angle glaucoma"]
| Precautions | ["May cause or exacerbate dyskinesias","May cause orthostatic hypotension","Risk of falls","May cause hallucinations and psychotic-like behavior","May cause impulse control disorders","May cause malignant melanoma (regular skin monitoring recommended)","Dopamine dysregulation syndrome","May cause sleep attacks/sudden onset of sleep","May cause excessive daytime sleepiness","May cause hyperpyrexia and confusion if abruptly discontinued (neuroleptic malignant syndrome-like symptoms)"] |
Loading safety data…
| Fetal Monitoring |
| Monitor maternal motor function, blood pressure, and signs of dyskinesias. Assess fetal growth and development via ultrasound. Consider fetal echocardiography for potential cardiac effects. Monitor for neonatal withdrawal syndrome (hypotonia, irritability) postpartum. |
| Fertility Effects | No direct evidence of impaired fertility in humans. Animal studies show altered reproductive parameters at high doses. In patients with Parkinson's, improved motor function may indirectly enhance fertility. Levodopa may increase prolactin, potentially affecting menstrual cycle. |